[1] Rotem S, Katz C, Benyamini H, et al. The structure and interactions of the proline-rich domain of aspp2. J Biol Chem, 2008,283:18990-18999.
[2] Mak VC, Lee L, Siu MK, et al. Downregulation of aspp2 in choriocarcinoma contributes to increased migratory potential through src signaling pathway activation. Carcinogenesis, 2013,34:2170-2177.
[3] Tordella L, Koch S, Salter V, et al. Aspp2 suppresses squamous cell carcinoma via rela/p65-mediated repression of p63. Proc Natl Acad Sci U S A, 2013,110:17969-17974.
[4] Wang Y, Godin-Heymann N, Dan Wang X, et al. Aspp1 and aspp2 bind active ras, potentiate ras signalling and enhance p53 activity in cancer cells. Cell Death Differ, 2013,20:525-534.
[5] Wang Z, Liu Y, Takahashi M, et al. N terminus of aspp2 binds to ras and enhances ras/raf/mek/erk activation to promote oncogene-induced senescence. Proc Natl Acad Sci U S A, 2013,110:312-317.
[6] Wilson AM, Morquette B, Abdouh M, et al. Aspp1/2 regulate p53-dependent death of retinal ganglion cells through puma and fas/cd95 activation in vivo. J Neurosci, 2013,33:2205-2216.
[7] Gorina S, Pavletich NP. Structure of the p53 tumor suppressor bound to the ankyrin and sh3 domains of 53bp2. Science, 1996,274:1001-1005.
[8] Alenzi FQ. Cell type specific expression of the apoptosis stimulating protein (aspp-2) in human tissues. Acta Microbiol Immunol Hung, 2010,57:419-429.
[9] Zhu C, Bao N, Chen S, et al. Dioscin enhances osteoblastic cell differentiation and proliferation by inhibiting cell autophagy via the aspp2/nf-kappabeta pathway. Mol Med Rep, 2017,16:4922-4926.
[10] Song B, Bian Q, Zhang YJ, et al. Downregulation of aspp2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation. Mol Cancer, 2015,14:177.
[11] Bergamaschi D, Samuels Y, Zhong S, et al. Mdm2 and mdmx prevent aspp1 and aspp2 from stimulating p53 without targeting p53 for degradation. Oncogene, 2005,24:3836-3841.
[12] Chen D, Padiernos E, Ding F, et al. Apoptosis-stimulating protein of p53-2 (aspp2/53bp2l) is an e2f target gene. Cell Death Differ, 2005,12:358-368.
[13] Zhao J, Wu G, Bu F, et al. Epigenetic silence of ankyrin-repeat-containing, sh3-domain-containing, and proline-rich-region- containing protein 1 (aspp1) and aspp2 genes promotes tumor growth in hepatitis b virus-positive hepatocellular carcinoma. Hepatology, 2010,51:142-153.
[14] Liu K, Shi Y, Guo X, et al. Chop mediates aspp2-induced autophagic apoptosis in hepatoma cells by releasing beclin-1 from bcl-2 and inducing nuclear translocation of bcl-2. Cell Death Dis, 2014,5:e1323.
[15] Liu K, Jiang T, Ouyang Y, et al. Nuclear egfr impairs aspp2-p53 complex-induced apoptosis by inducing sos1 expression in hepatocellular carcinoma. Oncotarget, 2015,6:16507-16516.
[16] Liu K, Lin D, Ouyang Y, et al. Amphiregulin impairs apoptosis-stimulating protein 2 of p53 overexpression-induced apoptosis in hepatoma cells. Tumour Biol, 2017,39:1010428317695026.
[17] Xu L, Tong X, Zhang S, et al. Aspp2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the src/fak/snail axis in hepatocellular carcinoma. Tumour Biol, 2016,37:13669-13677.
[18] Chen R, Wang H, Liang B, et al. Downregulation of aspp2 improves hepatocellular carcinoma cells survival via promoting becn1-dependent autophagy initiation. Cell Death Dis, 2016,7:e2512.
[19] Kemp L, Clare KE, Brennan PN, et al. New horizons in hepatitis b and c in the older adult. Age Ageing, 2018.
[20] Cao Y, Hamada T, Matsui T, et al. Hepatitis c virus core protein interacts with p53-binding protein, 53bp2/bbp/aspp2, and inhibits p53-mediated apoptosis. Biochem Biophys Res Commun, 2004,315:788-795.
[21] Xie F, Jia L, Lin M, et al. Aspp2 attenuates triglycerides to protect against hepatocyte injury by reducing autophagy in a cell and mouse model of non-alcoholic fatty liver disease. J Cell Mol Med, 2015,19:155-164.
[22] Lin M, Chang Y, Xie F, et al. Aspp2 inhibits the profibrotic effects of transforming growth factor-beta1 in hepatic stellate cells by reducing autophagy. Dig Dis Sci, 2018,63:146-154.
[23] Shi H, Zhang Y, Ji J, et al. Deficiency of apoptosis-stimulating protein two of p53 promotes liver regeneration in mice by activating mammalian target of rapamycin. Sci Rep, 2018,8:17927. |
